Soleno Therapeutics, Inc. (6XC.F)

37.48 -0.90 (-2.34%) At close: 03:29PM CEST

Soleno Therapeutics, Inc.

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444
https://soleno.life

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 33

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Corporate Governance

Soleno Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.